ABSTRACT

Introduction: The mechanisms of action of disease-modifying therapies (DMTs) for multiple sclerosis (MS) are complex and involve an interplay of immune system components. People with MS (PwMS) may lack a clear understanding of the immunological pathways involved in MS and its treatment; effective communication between healthcare professionals (HCPs) and PwMS is needed to facilitate shared decision-making when discussing the disease and selecting DMTs and is particularly important in the coronavirus disease 2019 (COVID-19) era.

Methods: In this patient-authored two-part review, we performed a targeted literature search to assess the need for better communication between HCPs and PwMS regarding treatment selection, and also conducted a

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40120-022-00349-5.
qualitative survey of four patient and care-partner authors to obtain insights regarding their understanding of and preferences for the treatment and management of MS.

**Results:** Following a search of the Embase and MEDLINE databases using Ovid in June 2020, an analysis of 40 journal articles and conference abstracts relating to patient empowerment and decision-making in DMT selection for MS showed a preference for safety and efficacy of treatments, followed by autonomy and convenience of administration. A need for better communication between HCPs and PwMS during treatment selection to improve patient satisfaction was also identified. The open survey responses from the patient authors revealed a need for greater involvement in decision-making processes and desire for improved communication and information tools.

**Conclusions:** This targeted literature search and phenomenological review confirms PwMS preferences for empowered decision-making in disease management and treatment selection, to optimize independence, safety, and efficacy. It also identifies an unmet need for improved communication and information tools that convey MS information in a relatable manner. Furthermore, this review seeks to address this unmet need by providing plain language figures and descriptions of MS immune mechanisms that can be used to facilitate discussions between HCPs and PwMS.

**PLAIN LANGUAGE SUMMARY**

In multiple sclerosis (MS), there are different cells in the immune system that contribute to the disease. The main cells in the immune system are T and B cells. People with MS (PwMS) might not be familiar with details about the immune system, and healthcare professionals might not always communicate details about how treatments work clearly to PwMS when choosing treatments with them. It is important for PwMS to have all the information they need to help make decisions about treatments. This information needs to be given in a way they can understand. This is especially important during the coronavirus disease 2019 (COVID-19) pandemic. In this paper, we first looked at what research has already been published about what is most important to PwMS when making treatment decisions. The existing research says that safety and effectiveness are the most important things and that PwMS prefer treatments that they can take themselves. PwMS also need better communication and information from doctors to make decisions and to help explain how MS treatments work in the body. Next, we gave a survey to the patients who are authors of this paper to ask about what is important to them when making treatment decisions. Their answers were very similar to the existing research. Overall, PwMS need better communication from healthcare professionals about the immune system. This paper also includes plain language descriptions and figures to help healthcare professionals explain and discuss the importance of the immune system in MS with PwMS.

**Keywords:** COVID-19; Disease-modifying therapies; Immunology; Mechanism of action; Multiple sclerosis; Patient engagement; Shared decision-making
Key Summary Points

Why carry out this study?
The mechanisms of action of disease-modifying therapies (DMTs) for multiple sclerosis (MS) are complex and involve an interplay of T cells, B cells, and other immune system components.

Informed, shared decision-making empowers people with MS (PwMS) and results in improved care, but many PwMS may not be familiar with or fully understand the immunological concepts involved, and healthcare professionals (HCPs) may not be able to communicate the concepts clearly.

What was learned from the study?
This study involved a targeted literature search to establish PwMS preferences for safety and efficacy of DMTs through routes that optimize independence, and to identify unmet needs for improved communication between HCPs and PwMS.

A qualitative survey of the patient authors of this work confirmed these findings and provided phenomenological insights into the decision-making process.

This review involving patient and care-partner authors further seeks to counter the identified unmet need for better communication by providing plain language explanations and figures of immune mechanisms in MS to serve as information tools for HCPs to use when communicating and discussing immune concepts with patients.

INTERACTIVE INFOGRAPHIC

This article contains an interactive infographic of the immune system in MS. To view it, click here: https://sn.pub/BOTxix.

INTRODUCTION

Multiple sclerosis (MS) is a chronic, progressive, immune-mediated disease characterized by demyelination of the central nervous system leading to neurological and physical disability [1, 2]. It is estimated that MS affects over 2.8 million individuals worldwide [3], and the prevalence in the USA has been estimated to be as high as 1 million people [4]. Owing to the complexity of the disease, theories of MS immunopathogenesis have evolved over the years, with current models focusing on the interplay of T and B cells, evidenced by the overlap of effects on these cell subsets by disease-modifying therapies (DMTs) [5].

Many people with MS (PwMS) may not be familiar or comfortable with MS terminology, including immunology and drug mode/machinery of action (MoA) terms [6]. However, given that healthcare professionals (HCPs) and PwMS consider many factors when selecting a DMT, such as efficacy, safety, administration route, and frequency, broader comprehension of MS immunology and terminology would be useful. A better understanding of potential treatment effects may lead to more informed decision-making when choosing DMTs. However, the importance and relevance to PwMS of comprehending these concepts in informing choices when selecting new DMTs is not currently known. Moreover, PwMS’ understanding of how DMTs can affect B and T cells, and interpretations of risk and administration preferences for therapies, may have been influenced by the coronavirus disease 2019 (COVID-19) pandemic. While safety and efficacy may be expected to take precedence over MoA knowledge in PwMS’ considerations of DMTs, understanding treatment MoAs can meaningfully inform safety and efficacy, and there is a clear need for such information to be more clearly and consistently accessible, in terms of both
content and methods of communication. These concepts were initially identified and explored in a poster presented at the MS Virtual 8th Joint ACTRIMS-ECTRIMS Meeting 2020 [7].

The Immune System in MS

While MS pathogenesis is highly complex and not fully elucidated, it is understood to be mediated in part by the interplay and balance of B and T cells [5]. In MS, multiple immunological and inflammatory processes, including axonal damage and demyelination, gliosis, cortical neurodegeneration, and neuronal loss, result in atrophic lesions in the brain [8, 9]. These processes are largely driven by: (1) effector B cells and B-cell lineage plasmablasts and plasma cells generating autoreactive oligoclonal antibodies, (2) circulatory cytotoxic T cells that have migrated across the blood–brain barrier, and (3) complement elements and other innate components of the immune system such as microglia and inflammatory mediators such as cytokines [8, 9]. Furthermore, there is an imbalance in the regulatory T and B cells that usually keep these inflammatory and cytotoxic processes in check and maintain immunological homeostasis, resulting in unregulated immune-mediated tissue damage (Fig. 1) [10]. See “Box 1” for a lay language explanation of MS immunology.

Box 1. The Immune System in MS

In multiple sclerosis (MS), there is destruction of the protective coating of the nerves. This protective coating is called the myelin sheath, and it is made up of individual myelin cells. This process of destruction is called “demyelination” and referred to as “lesions” or areas of brain damage. There is also more general inflammation and destruction of the brain cells, particularly the neurons. This is sometimes referred to as “atrophy.” Some of the demyelination and atrophy is caused by signals from the immune system that kill or damage the myelin cells, neurons, and other brain cells. These immune signals normally protect the body from infections, but in autoimmune diseases such as MS, they lead to the immune system’s mistakenly attacking the body’s own cells. Immune cells that target the body’s own cells are known as “autoreactive.”

There are several types of immune signals, and they come from different cells of the immune system. The two main types of immune cells that are involved in MS are called “B cells” and “cytotoxic T cells.” “Cytotoxic” means that something is toxic to cells. Other immune cells also play a role, such as “regulatory T and B cells,” which are important for stopping other cells from sending too many damage signals. This helps create a balance between immune responses that are too strong or too weak (Fig. 1a). Usually, B cells produce types of molecules called “antibodies” that travel in the blood and help fight infections. Cytotoxic T cells deliver the damage signal directly to infected cells using molecules on the surface of the T cell (Fig. 1b). In MS, B cells, antibodies, and cytotoxic T cells can mistakenly kill or damage myelin cells, neurons, and other brain cells. “Complement” and “cytokines” are other types of damaging molecules made by other cells of the immune system that can also cause general inflammation, atrophy, and demyelination. In MS, the overall balance between damaging cells and regulating cells is lost (Fig. 1c).

Disease-Modifying Therapies and Their Mechanisms of Action

DMTs are immunomodulatory therapies that can change or alter the MS disease course by reducing the number of relapses, reducing the appearance of new lesions on magnetic resonance imaging, and slowing progression and atrophy [11, 12]. Recent evidence has shown that there is significant interplay and an overlap of the effects of DMTs between lymphocyte subsets [5, 13]. The relationship between B and T cells is highly complex, and introducing immune modulation into this system can have clear impacts on the balance of these cell populations. At the time of publication, there are 22
branded or generic variations of DMTs approved by the US food and Drug Administration for the treatment of relapsing MS, which can be summarized into five overall drug categories based on their immunomodulatory effects (Table 1) [14].

The majority of DMTs have direct impacts on most lymphocytes, but some can target specific populations. The small-molecule modulators of the sphingosine-1-phosphate receptor prevent egress of autoreactive T cells from the lymph nodes and downregulate inflammatory mechanisms. However, non-lymphatically sequestered cells such as circulatory effector B cells are known to be unaffected by this MoA [15–17]. Anti-α4-integrin monoclonal antibodies prevent endothelial migration of lymphocytes across the blood–brain barrier into the central nervous system. Anti-CD52 monoclonal and DNA synthesis and repair inhibitors are immunosuppressive and immunomodulatory agents that mediate lymphocyte depletion of both B and T cells [15]. However, there are also B-cell-specific depletion therapies, anti-CD20 monoclonal antibodies, that act mostly on B lineage cells; Bruton’s tyrosine kinase inhibitors are also being investigated as potential B-cell-

![Fig. 1 The balance of the adaptive immune system and MS. a The resting immune system. On one side, inflammatory and reactive mechanisms limit infections and respond to foreign antigen. On the other side, regulatory mechanisms keep the adaptive response in check and maintain a homeostatic balance. b The immune system during an infection. The infection has already shifted the balance towards tolerance, so inflammatory and reactive mechanisms are upregulated to fight the infection and restore homeostasis. Regulatory mechanisms are downregulated. c The immune system in MS. The balance is shifted towards autoimmunity and autoreactivity, but the regulatory homeostatic mechanisms are not sufficient to curb the immune responses. Autoreactive lymphocytes migrate into the central nervous system and through a number of pathogenic mechanisms cause widespread demyelination, gliosis, and neurodegeneration, forming lesions of atrophic brain tissue. MS multiple sclerosis](image)

| Immunomodulatory effect                                                                 | General mechanism of action                          | Route of administration |
|----------------------------------------------------------------------------------------|------------------------------------------------------|-------------------------|
| Prevention of lymphocyte egression from lymph nodes, i.e., retention of lymphoid cells in the lymph nodes | S1P receptor downregulation                          | Oral                    |
| Prevention of lymphocytic endothelial migration                                        | Anti-α4-integrin monoclonal antibody                 | Infusion                |
| Lymphocyte depletion                                                                   | Anti-CD52 monoclonal antibody                        | Infusion                |
|                                                                                       | DNA synthesis and repair inhibition                  | Oral and infusion       |
| B-cell-specific depletion                                                              | Anti-CD20 monoclonal antibody                        | Infusion and injection  |
| Suppression of inflammatory processes                                                  | Myelin basic protein mimicry                         | Injection               |
|                                                                                       | Nrf2 pathway downregulation                          | Oral                    |
|                                                                                       | Interferon receptor activation                       | Injection               |

CD cluster of differentiation, FDA Food and Drug Administration, MS multiple sclerosis, Nrf2 nuclear factor erythroid 2-related factor 2, S1P sphingosine-1-phosphate

Table 1 Categories of FDA-approved disease-modifying therapies for MS [14]
specific therapies [18]. Finally, fumarate therapies, interferon therapies, and glatiramer acetate all act to suppress and mitigate inflammatory processes via nuclear factor erythroid 2-related factor 2 pathway downregulation, interferon receptor activation, and myelin basic protein mimicry, respectively (Fig. 2). See “Box 2” for a lay language explanation of DMT MoAs.

**Box 2. How DMTs Work**

Disease-modifying therapies (DMTs) work by acting on different cells or molecules of the immune system to affect the balance of “reactive” immune cells versus “regulating” immune cells. Immune cells that react to the body’s own cells are known as “autoreactive.” Most DMTs work by reducing the ability of autoreactive immune cells to kill or damage myelin cells, neurons, and other brain cells. Others work by improving the ability of regulating cells to control the immune system. Some DMTs can be designed to target specific cells of the immune system. But, because the immune system is very complex, some studies show that DMTs can also affect other cells as well as the overall balance of the immune system (Fig. 2).

In MS, B and T cells leave the lymph nodes and move from the blood into the brain and spinal cord to cause damage. This is known as crossing the “blood–brain barrier.” Some DMTs work by preventing the autoreactive B and T cells from leaving the lymph nodes (1). Other DMTs work by stopping the autoreactive B and T cells from crossing the blood–brain barrier (2). These DMTs prevent B and T cells that are autoreactive from traveling around the body, but still let other cells that
are not autoreactive fight infections. Other DMTs work by killing any autoreactive B and T cells that are traveling around the body. This is known as "immune depletion." There are also DMTs that work by destroying B and T cells (3). Some of these DMTs work by killing lymphocytes that have a protein called CD20, which are mostly B cells (4). Finally, glatiramer acetate, fumarate therapies, and interferon therapies work by reducing inflammation or helping the regulating parts of the immune system control the autoreactive immune responses (5 and 6).

REVIEW AIM

This review aims to assess and to evaluate the level of PwMS involvement in MS treatment selection, the importance for PwMS to understand MoA when discussing DMTs with HCPs, and to gain insights from PwMS and physicians to provide a wider context for treatment selection conversations. This review explores the existing literature and presents the findings of a survey in PwMS to establish existing preferences for DMT selection and shared decision-making processes, and to define the unmet need for better PwMS–HCP communications. By exploring the factors most important to PwMS, care partners and physicians when considering potential DMTs, this review will help to educate HCPs on the benefits of shared decision-making and how to have meaningful MoA conversations with PwMS. Ultimately, the goal is to support improved shared decision-making regarding DMT selection between PwMS and their HCPs.

METHODS

Targeted Literature Review

The targeted literature search was performed in June 2020 using Ovid in the Embase and MEDLINE databases of all available English-language articles and conference abstracts with no time limit using the following search terms:

1. (Patient or stakeholder).ti.
2. (Perspective$ or insight$ or understanding or knowledge or engag$ or empower$ or preference$ or communicat$).ti.
3. Multiple sclerosis.ti.
4. ("disease modifying therap$" or "disease modifying treatment").af.
5. ("mechanism of action" or "mode of action").af.
6. 1 and 2 and 3.
7. 1 and 2 and 3 and 4.
8. 1 and 2 and 3 and 5.

Further, manual searches were performed using different combinations of the above search terms on PubMed. Titles were initially screened manually for duplication and direct relevance to the current objective. Reference lists were also screened for any further titles that were of relevance. The remaining resources were then categorized according to their methods (qualitative, quantitative, or review) and analyzed in full. See "Box 3" for a lay language explanation of the methods.

Box 3. How to Search the Scientific Literature

In research, “the literature” means all existing research that has been published in scientific journals. You can do your own literature search using the PubMed website: https://pubmed.ncbi.nlm.nih.gov.

Here, you can read abstracts of articles for free, but you may need to pay a fee to read some of the articles in full. When searching, you can use “Boolean operators” to combine multiple searches:

- AND, which combines results for all search terms
- OR, which combines results that have at least one search term
- NOT, which excludes a search term you do not want to be included.

Adding ".ti" at the end tells the search engine to show only results with the search term in the title, while ".af" shows results with the search term in any search field. You can also use Medical Subject Headings.

△ Adis
(MeSH) to help narrow the results. These are scientific terms for different medical problems used by healthcare professionals. You can read more about MeSH terms at the National Library of Medicine website: https://meshb.nlm.nih.gov/search.

Survey and Correspondence Insights

The specific methods of data collection for the questionnaire have been presented elsewhere [7]. In brief, a qualitative questionnaire was designed by two authors (A.R. and J.L.W.) in December 2018 based on preliminary discussions with the patient authors. This was designed to explore factors most important to PwMS when considering potential DMTs following a phenomenological PwMS narrative approach. This included PwMS' understanding of the immunological processes of MS and the MoAs of MS treatments, and preferences regarding route of administration and provision of MS clinical information. The questionnaire was distributed via email to three PwMS (J.B., D.C., and T.S.) and one care partner (J.C.) based on their advocacy expertise and involvement in the patient-authored literature, all of whom are authors of this work. General insights were gathered from the HCP authors (two neurologists [J.G. and A.Z.O.], a pediatric neurologist [M.L.S.], and a physician assistant [J.K.]) via personal correspondence, based on their professional expertise and established relationships. Ethics committee approval was not required for this survey, which was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All survey respondents who are also authors of this publication provided informed consent to participate in the survey and for their responses to be included in this publication. This was a noninterventional qualitative survey conducted by Novartis in the USA to assess PwMS and HCP opinion. The research followed General Data Protection Regulation guidance. Survey respondents did not receive any incentive payment for completion of the survey, and all participated as authors in the development of this manuscript, in compliance with the International Committee of Medical Journal Editors authorship requirements and Good Publication Practice.

RESULTS

Targeted Literature Review

The search string [(patient or stakeholder).ti.; (perspective$ or insight$ or understanding or knowledge or engag$ or empower$ or preference$ or communicat$).ti.; multiple sclerosis.ti. AND (“disease modifying therap$” or “disease modifying treatment”).af.]} yielded 39 results on Ovid. Following screening for relevance to the current objective and the removal of duplicates, this was then narrowed down to 20 articles for review. The search string [(patient or stakeholder).ti.; (perspective$ or insight$ or understanding or knowledge or engag$ or empower$ or preference$ or communicat$).ti.; multiple sclerosis.ti. AND (“mechanism of action” or “mode of action”).af.]} did not yield any results, confirming the unmet need for assessment of PwMS' understanding of MoA. Subsequently, manual searching of the literature on PubMed using the same keywords yielded an additional 6 articles, and full-text review of all search results and the reference lists identified 14 more articles with relevance to the current objective. In all, 40 journal articles and conference abstracts are included in the current review (Fig. 3; Table 2).

Of the 40 journal articles and conference abstracts in the analysis, 5 were review articles [19–23] (including 2 systematic reviews [22, 23]) and 6 were of a qualitative nature, primarily ethnographic and phenomenological studies [24–29]. The remaining 29 publications were quantitative surveys or discrete-choice experiments and conjoint analyses—common statistical methods for ranking attributes within preferences [30–58].

Independence and convenience of administration are recognized as critical factors in selecting DMTs to initiate therapy or to switch therapy; accordingly, 12 of the quantitative items and 3 qualitative items found a preference or perceived suitability for oral administration, ranging from 31% to 93% of surveyed PwMS
cohorts preferring this method [24, 27, 28, 30–41]. Overall, 6 quantitative and 5 qualitative items explored the role of PwMS–HCP communications in shared decision-making and patient satisfaction with the level of engagement [24, 25, 27–29, 42–47]. In the phenomenological studies, the majority of PwMS were actively involved in decision-making, considered their neurologist a useful figure in their MS treatment path, and were the key drivers of DMT decisions. Across the analyses, technology and education were identified as principal factors for optimizing communication within health services and improving overall patient satisfaction. It is widely acknowledged in the literature and in the medical community that patient satisfaction and understanding can lead to improved treatment adherence and better health outcomes.

### Patient Survey and HCP Insights

In addition to the literature review, a preliminary qualitative survey was undertaken to obtain perspectives and insights from PwMS and HCPs on the importance of understanding the MoAs of DMTs. The results from the survey may be helpful in informing and designing future studies that will assess these needs more widely. The full responses to the open-response questions are presented in the Supplementary Material. Overall, the PwMS and care-partner respondents were largely in agreement with the current literature, reporting that safety and efficacy are equally the most important attributes to consider when making DMT decisions, and that routes and modes of administration that offer independence are preferable to those that require HCP oversight.

“\textit{A large factor in selecting a medication is how well will it treat my MS and prevent further progression. Next, I want to know the side effects of the medication and how will it affect my body overall. I like to know what are the large concerns [when] taking a medication and short term [concerns]. Another priority is the method in which you deliver the medication. For example, a pill, infusion, or shot. Finally, how often the medication is required to take. For example, daily, weekly, monthly, etc.}” (Tim Sabutis)

“If [efficacy] and side effects are all equal then I suppose I wouldn’t care too much about how it works. I would like to know what it would be doing to my body, but in the end, if it’s all..."
| Author(s) | Title | Publication details | Source | Summary of paper |
|-----------|-------|---------------------|--------|------------------|
| Adlard et al. [30] | Patient preferences for different modes and frequency of administration of multiple sclerosis disease modifying therapies | *Value Health*. Conference: ISPOR Europe 2018: New perspectives for improving twenty-first century health systems. 2018;21(3):S351. https://doi.org/10.1016/j.jval.2018.09.2096 | Embase | A quantitative discrete choice experiment/conjoint analysis of 140 PwMS on administration variables, showing a preference for oral administration |
| Agashivala et al. [48] | Compliance to fingolimod and other disease modifying treatment in multiple sclerosis patients, a retrospective cohort study | *BMC Neurol.* 2013;13:138. https://doi.org/10.1186/1471-2377-13-138 | References | A quantitative retrospective claims analysis of 1891 claims on DMTs adherence, showing improved adherence to orally administered treatments |
| Bayas and Mäurer [19] | Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence | *Patient Prefer Adher.* 2015;9:265–274. https://doi.org/10.2147/PPA.S61651 | Embase | A review of teriflunomide adherence |
| Bergmann et al. [31] | Patient preferences in the choice of disease modifying drugs for multiple sclerosis | *Neurology*. Conference: 66th American Academy of Neurology Annual Meeting, AAN. 2014;82(10.1). P3.137 | Embase | A quantitative discrete choice experiment/conjoint analysis of 1628 PwMS on DMT preferences, showing a 63% preference for oral administration |
| Bergvall et al. [49] | Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis | *J Med Econ.* 2014;17(10):696–707. https://doi.org/10.3111/13696998.2014.940422 | References | A quantitative retrospective claims analysis of 3750 claims on DMT adherence, showing improved adherence to orally administered treatments |
### Table 2 continued

| Author(s) | Title | Publication details | Source | Summary of paper |
|-----------|-------|---------------------|--------|------------------|
| Bottomley et al. [36] | A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in multiple sclerosis | *J Med Econ.* 2017 Aug;20(8):863–870. [https://doi.org/10.1080/13696998.2017.1336099](https://doi.org/10.1080/13696998.2017.1336099) | PubMed | A quantitative discrete choice experiment/conjoint analysis of 250 PwMS on significant risks associated with DMTs, showing a 31% preference for oral administration |
| Carlin, Higuera, and Anderson [32] | Improving patient-centred care by assessing patient preference for multiple sclerosis disease-modifying agents: a stated-choice experiment | *Perm J.* 2017;21:16–102. [https://doi.org/10.7812/TPP/16/102](https://doi.org/10.7812/TPP/16/102) | Embase | A quantitative discrete choice experiment/conjoint analysis of 537 PwMS on DMT preferences, showing a preference for oral administration |
| Clark et al. [40] | Understanding disease-modifying therapy administration route suitability in different multiple sclerosis patient segments in the 5EU and US | *Value Health.* Conference: ISPOR 2019. 2019;22(2):5378. [https://doi.org/10.1016/j.jval.2019.04.1845](https://doi.org/10.1016/j.jval.2019.04.1845) | Embase | A quantitative survey of 2734 neurologists on suitability of different routes of administration for PwMS, showing a preference for oral administration |
| Colligan, Metzler, and Tiryaki [20] | Shared decision-making in multiple sclerosis | *Mult Scler.* 2017 Feb;23(2):185–190. [https://doi.org/10.1177/1352458516671204](https://doi.org/10.1177/1352458516671204) | PubMed | A review of shared decision-making processes |
| De Ceunick Van Capelle et al. [24] | A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT’s) in multiple sclerosis (MS) | *PLoS ONE.* 2017;12(8):e0182806. [https://doi.org/10.1371/journal.pone.0182806](https://doi.org/10.1371/journal.pone.0182806) | Embase | A qualitative phenomenology of 10 PwMS on DMT decision-making, showing a preference for oral administration and active engagement in decision-making |
| De Seze, Borgel, and Brudon [42] | Patient perceptions of multiple sclerosis and its treatment | *Patient Prefer Adher.* 2012;6:263–73. [https://doi.org/10.2147/PPA.S27038](https://doi.org/10.2147/PPA.S27038) | PubMed | A quantitative survey of 202 PwMS on perceptions and experiences of MS, showing a desire for increased HCP communication |
| Author(s)       | Title                                                                 | Publication details                                                                 | Source          | Summary of paper                                                                 |
|----------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------|----------------------------------------------------------------------------------|
| Falet et al. [25] | A qualitative study of patient perspectives regarding the role of the neurologist in advanced multiple sclerosis | *Can J Neurol Sci.* Conference: 53rd Annual Congress of the Canadian Neurological Sciences Federation. 2018;45(2):S24. [https://doi.org/10.1017/cjn.2018.133](https://doi.org/10.1017/cjn.2018.133) | Embase          | A qualitative phenomenology of 18 PwMS on perceptions of the role of neurologists, showing that neurologists are perceived as useful figures in healthcare |
| Garcia-Dominguez et al. [33] | Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment | *Patient Prefer Adher.* 2016;10:1945–56. [https://doi.org/10.2147/PPA.S114619](https://doi.org/10.2147/PPA.S114619) | Embase          | A quantitative discrete choice experiment/conjoint analysis of 125 PwMS on risk acceptability, showing a preference for oral administration |
| Glusman et al. [43] | Patient-provider communication and perceived autonomy support among multiple sclerosis patients who discontinue disease modifying therapy against medical advice | *Mult Scler.* Conference: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS. 2015;23(11):278. ECTRIMS Online Library: 116267;2025 | Embase          | A quantitative survey of 104 PwMS on perceived autonomy, showing improved communication and autonomy in PwMS who were treatment-adherent |
| Heesen et al. [50] | Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists | *Mult Scler.* 2010;16(12):1507–12. [https://doi.org/10.1177/1352458510379819](https://doi.org/10.1177/1352458510379819) | References      | A quantitative survey of 69 PwMS and 66 neurologists on risk perceptions of natalizumab, showing PwMS were more accepting of natalizumab-associated risks than HCPs |
| Heesen et al. [21] | Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement | *J Neurol Sci.* 2011;306:192–7. [https://doi.org/10.1016/j.jns.2010.09.12](https://doi.org/10.1016/j.jns.2010.09.12) | References      | A review of DMT decision-making processes                                                                                                                                                                       |
| Author(s) | Title | Publication details | Source | Summary of paper |
|-----------|-------|---------------------|--------|------------------|
| Hincapie, Penm, and Burns [34] | Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis | *J Manag Care Spec Pharm.* 2017;23(8):822–30. https://doi.org/10.18553/jmcp.2017.23.8.822 | Embase | A quantitative discrete choice experiment/conjoint analysis of 129 PwMS on significant treatment risks, showing a preference for oral administration |
| Johnson et al. [26] | Patient perspective on disease-modifying therapy in multiple sclerosis | *Int J MS Care.* 2006;8(1):11–18. https://doi.org/10.7244/1537-2073-8.1.11 | References | A qualitative phenomenology of 18 PwMS on DMT preferences, showing that there are significant barriers to DMT initiation and adherence |
| Johnson et al. [51] | Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy | *J Neurol.* 2009;256:554–62. https://doi.org/10.1007/s00415-009-0084-2 | References | A quantitative discrete choice experiment/conjoint analysis of 651 PwMS on risk acceptability, showing an acceptance of risk in return for efficacy |
| Jonker et al. [35] | Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options | *Med Decis Making.* 2020;40(2):198–211. https://doi.org/10.1177/0272989X2987944 | Embase | A quantitative discrete choice experiment/conjoint analysis of 1162 PwMS, showing a 41% preference for oral administration |
| Kasper et al. [52] | Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial | *Eur J Neurol.* 2008;15:1345–52. https://doi.org/10.1111/j.1468-1331.2008.02313.x | References | A quantitative randomized controlled trial of 297 PwMS on informational interventions, showing the type of informational intervention did not affect the HCP-PwMS dynamic nor the treatment choices |
| Köpke et al. [53] | Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial | *J Neurol Neurosurg Psychiatry.* 2014;85:411–18. https://doi.org/10.1136/jnnp-2013-306441 | References | A quantitative randomized controlled trial of 192 PwMS on informational interventions, showing the informational interventions improved informed choice |
| Author(s) | Title | Publication details | Source | Summary of paper |
|----------|-------|---------------------|--------|------------------|
| Nazareth et al. [44] | Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey | *Mult Scler Relat Dis.* 2018;26:219–34. [https://doi.org/10.1016/j.msard.2018.09.002](https://doi.org/10.1016/j.msard.2018.09.002) | Embase | A quantitative survey of 5311 PwMS on HCP engagement during relapses, showing improved satisfaction with increased HCP engagement |
| Poulos et al. [54] | Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment | *Patient.* 2016;9:171–80. [https://doi.org/10.1007/s40271-015-0136-x](https://doi.org/10.1007/s40271-0136-x) | References | A quantitative discrete choice experiment/conjoint analysis of 189 PwMS on variables associated with injectables, showing injection frequency may be as important as safety and efficacy |
| Poulos et al. [55] | A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany | *Ther Adv Neurol Disord.* 2016;9(2):95–104. [https://doi.org/10.1177/1756285615622736](https://doi.org/10.1177/1756285615622736) | Embase | A quantitative discrete choice experiment/conjoint analysis of 205 PwMS on variables associated with injectables, showing injection frequency may be as important as safety and efficacy |
| Reen, Silber, and Langdon [22] | Multiple sclerosis patients’ understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review | *J Neurol Sci.* 2017;375:107–22. [https://doi.org/10.1016/j.jns.2016.12.038](https://doi.org/10.1016/j.jns.2016.12.038) | PubMed | A systematic review of 22 publications on MS understanding, showing HCP–PwMS communications may not be adequate to convey understanding |
| Rieckmann et al. for the Members of the MS in the 21st Century Steering Group [29] | Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group | *Mult Scler Relat Disord.* 19:153–60. [https://doi.org/10.1016/j.msard.2017.11.013](https://doi.org/10.1016/j.msard.2017.11.013) | PubMed | A qualitative steering group workshop insights collection of 11 PwMS and 10 HCPs on PwMS–HCP relationships, showing that technology and education are principal factors for positive impact, and communication maximizes health services |
| Author(s)                | Title                                                                 | Publication details                                      | Source          | Summary of paper                                                                 |
|-------------------------|-----------------------------------------------------------------------|----------------------------------------------------------|------------------|---------------------------------------------------------------------------------|
| Rinón et al. [45]       | The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis | *Patient Prefer Adher.* 2011;5:629-43. https://doi.org/10.2147/PPA.S26479 | References      | A quantitative survey of 331 PwMS and 280 neurologists on DMT adherence, showing that communication is needed to improve adherence |
| Schlegel and Leray [27] | From medical prescription to patient compliance: a qualitative insight into the neurologist-patient relationship in multiple sclerosis | *Int J MS Care.* 2018;20(6):279-86. https://doi.org/10.7224/1537-2073.2017-043 | PubMed          | A qualitative phenomenology of 29 PwMS on neurologist-PwMS relationships, showing a preference for oral administration, and that over half chose their own treatments |
| Sempere et al. [46]     | Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study | *Patient Prefer Adher.* 2017;11:995-9. https://doi.org/10.2147/PPA.S129356 | Embase          | A quantitative discrete choice experiment/conjoint analysis of 37 PwMS, showing involvement in shared decision-making was considered adequate |
| Serafini, Jones, and Pike [41] | Assessment of patient preferences in the treatment of relapsing–remitting multiple sclerosis in public and private systems in Latin America | *Value Health.* Conference: ISPOR 19th Annual European Congress. 2016;23(2):A435. https://doi.org/10.1016/j/jval.2016.09.513 | Embase          | A qualitative survey of 417 PwMS on route of administration preferences, showing a preference for oral administration |
| Tencer et al. [28]      | Neurologist and patient preferences in multiple sclerosis: UK and US qualitative research findings | *Value Health.* Conference: ISPOR Europe 2019. 2019;22(3):5757. https://doi.org/10.1016/j/jval/2019/09/1977 | Embase          | A qualitative phenomenology of 20 PwMS and 20 neurologists on treatment considerations, showing a 60% preference for oral administration and that treatment choice is largely driven by PwMS |
| Author(s) | Title | Publication details | Source | Summary of paper |
|-----------|-------|---------------------|--------|-----------------|
| Thakur, Manuel, and Tomlinson [56] | Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro TM 30G and Betacomfort R devices | Pragmat Obs Res. 2013;4:19–26. https://doi.org/10.2147/POR.S51838 | MEDLINE | A quantitative survey of 201 PwMS on autoinjectable preferences, showing PwMS value reliability and convenience of administration |
| Tintore et al. [47] | The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction | Patient Prefer Adher. 2017;11:33–45. https://doi.org/10.2147/PPA.S115090 | Embase | A quantitative survey of 982 PwMS and 900 neurologists on satisfaction with DMTs and the decision-making process, showing that PwMS who were more satisfied with their DMTs were more comfortable having open dialogue with their HCPs |
| Utz et al. [37] | Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis | Ther Adv Neurol Disord. 2014;7(6):263–75. https://doi.org/10.1177/1756285614555335 | References | A quantitative discrete choice experiment/conjoint analysis of 319 PwMS on oral versus parenteral administration variables, showing a 93% preference for oral administration |
| Visser et al. [23] | Patient needs and preferences in relapsing–remitting multiple sclerosis: a systematic review | Mult Scler Relat Dis. 2020;39:101929. https://doi.org/10.1016/j.msard.2020.101929 | Embase | A systematic review of 24 publications on DMT preferences, showing that HCP understanding of PwMS’ values is needed to improve adherence |
| Wicks et al. [57] | US patient perspectives on the multiple sclerosis treatment experience: results of a US web-based survey | Mult Scler. Conference: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS. 2015;23(11.1):278. ECTRIMS Online Library: 115368;173 | Embase | A quantitative survey of 943 PwMS on DMT initiation and discontinuation factors, showing that treatment decisions are multifactorial |
equally safe and effective, how it works would not matter much." (Daisy Clemmons)

“I remember before there was a pill form of treatment for MS and the MS community was begging to know when it would be available. The answer was always “in 5 years”. I don’t know anyone who would choose an injection or infusion over a pill. It seems like there is less risk involved during administration to only swallow a pill. I’d rather be at home and take the pill myself.” (Jeri Burtchell)

With regard to immunological terms and drug MoAs, PwMS and care-partner respondents felt they had a better understanding of overall processes (e.g., of the overarching role of the immune system in MS) than they did of specific mechanisms (such as the interplay of T cells and B cells and their role in MS pathophysiology). It was recognized that MoA knowledge among the patient respondents is currently lacking but represents an area of interest in which to build communication and develop educational material.

“I feel like I have a strong grasp of demyelination vs inflammation in MS. I have done a lot of research on MS and the disease-modifying drugs. The role of B cells vs T cells is something I have not done much research on, however, but am very eager to learn more as B cells become more of a target in emerging therapies. I have some idea of what biologics are and how they work but not a solid understanding…I’ve always been curious about the mechanism of action with any drug I take,

Table 2 continued

| Author(s)      | Title                                                                 | Publication details                                      | Source    | Summary of paper |
|----------------|----------------------------------------------------------------------|----------------------------------------------------------|-----------|------------------|
| Wicks et al. [58] | Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients | *Interact J Med Res.* 2015;4(1):e6. https://doi.org/10.2196/ijmr.3776 | References | A quantitative discrete choice experiment/conjoint analysis of 319 PwMS on oral administration variables, showing that HCPs need to understand PwMS values to address treatment concerns |
| Wilson et al. [38] | Patient centred decision making: use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices | *J Neurol Sci.* 2014;344:80–7. https://doi.org/10.1016/j/jns.2014.06.030 | References | A quantitative discrete choice experiment/conjoint analysis of 291 PwMS on risk acceptability, showing a preference for oral administration |
| Wilson et al. [39] | Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis | *Int J MS Care.* 2015;17(2):74–82. https://doi.org/10.7224/1537-2073.2103-053 | References | A quantitative discrete choice experiment/conjoint analysis of 50 PwMS, showing a preference for oral administration |

DMT disease-modifying therapy, HCP healthcare professional, MS multiple sclerosis, PwMS people with multiple sclerosis
whether it’s for a migraine or for MS. I feel like knowing how drugs work allows me to make better informed choices when it comes to selecting treatments. Understanding the MoA can also shed more light on why certain side effects may be likely to occur. Knowledge is power and when you have a chronic illness like MS it’s important to learn all you can about every aspect of the disease and how it’s treated... While I feel like I know a lot about MS and about the various treatment options, I know little about their MoAs and what makes B cells or T cells the best targets for treatments. I would love to learn more, especially when it comes to targeted therapies and knowing what works best for an individual based on their type of MS and unique set of symptoms or circumstances.” (Jeri Burtchell)

Patient and HCP respondents all reported that face-to-face discussions, supplemented with visual aids such as animations, were preferable to noninteractive materials such as leaflets and websites; one patient further identified the environmental impacts of paper distribution as a negative factor. Crucially, the survey and subsequent correspondence identified the necessity for information delivery to be tailored to the needs of individuals.

“Having information about how the treatment works explained to me by a medical professional using patient-friendly language would be the best option. This allows me to ask questions and get immediate clarification. Websites and videos can also provide FAQ-type answers and be a resource that is readily accessible 24/7 when I may not be able to contact my doctor. Everyone has their own learning style and others may feel having a leaflet is important. I am more visual and would like to have an explainer video that walks me through how a treatment works. I am also trying to become more environmentally conscious and would probably not take a leaflet if I can avoid it. I prefer digital over paper when possible.” (Jeri Burtchell)

“[I think it is important to use the mode of learning that is effective for the patient. For me, watching and seeing a video is the most effective strategy for me to learn. It is important for the care professional to meet the client where they best learn to communicate about the disease-modifying treatments.” (Tim Sabutis)

“I would prefer a medical professional in case I have questions. They would be able to give an explanation tailored for my needs when trying to understand.” (Daisy Clemmons)

In addition, HCP respondents identified the need for increased face-to-face time in the clinic to allow for such conversations to take place.

“Increased access to technology, credit for time spent on phone, and more face-to-face time in clinic is always needed.” (Michael L Sweeney)

“Providers need more time for education.” (Jennifer Graves)

“[It is important to spend] time on discussing a personalized approach in therapy selection and shared decision [making] with [the] patient.” (Ahmed Z. Obeidat)

**DISCUSSION**

The findings from the targeted literature search and qualitative survey employed in this review were largely in agreement, and were consistent with the literature regarding PwMS preferences; the findings from both methods highlight a knowledge gap in the importance of understanding MoA immunology by PwMS when making DMT decisions, which this review aims to address in part. The perspectives from the HCP and PwMS authors were also aligned, demonstrating a need for more resources for communication of such concepts, personalized education, and a desire from PwMS for improved health literacy.

Moreover, the findings from both of the methods confirmed expectations of safety and efficacy taking priority in determining factors of DMT decision-making, followed by methods of administration, with the majority of PwMS reporting a preference for methods that allow for autonomy and independence (e.g., oral administration or treatment that can be administered at home).

This desire for more independence in administration represents a wider shift in
philosophies of medical practice, favoring patient empowerment and shared decision-making over the more traditional, paternalistic approaches to delivering healthcare. Shared decision-making is a critical aspect of enabling patients to make fully informed healthcare choices [59]. This cooperative approach is particularly important and advantageous for preference-sensitive conditions with a wide range of treatment options that vary in their attributes, such as MS [20]. The evidence base for the efficacy of shared decision-making models, patient engagement practices, and health literacy approaches in MS specifically is limited but has been presented in a Cochrane Library systematic review, concluding that information provision in MS leads to improved disease-related knowledge compared with no information provision [60]. In the UK, both the National Health Service and the National Institute for Health and Care Excellence assert that shared decision-making has the potential to lead to improved health outcomes for patients [61, 62]. Regardless, the need for shared decision-making is not solely evidence-based but is also an ethical and moral imperative.

However, successful shared decision-making is dependent both on sufficient health literacy among patients and on satisfactory communication and materials from HCPs. In a recent meeting where multiple stakeholders gathered to identify unmet areas of need in MS care, the Members of the MS in the 21st Century Steering Group highlighted the urgent need for improved patient engagement in MS care and research [29]. Many resources exist to aid the delivery of healthcare centered around shared decision-making, notably the Armstrong 2016 Framework for Shared Decision-Making and Neurology, which presents a stepwise approach to: (1) identify a patient's values and goals, (2) present evidence as it relates to their values and goals, and (3) arrive at a decision with the patient [63]. Many other educational programs, decision support techniques, health literacy tools, and treatment-specific decision aids have also been developed to enable shared decision-making healthcare, to provide language for effectively communicating MS concepts, and ultimately to empower PwMS to arrive at a fully informed healthcare decision [20, 64].

Furthermore, the COVID-19 pandemic has resulted in significant interruptions to the normal delivery of healthcare across all specialties and has introduced many uncertainties, particularly in the treatment of immunological and autoimmune conditions. Immunomodulatory and immunosuppressive therapies are known to incur risks associated with infectious disease, although the exact interactions of COVID-19 with DMTs for MS are largely unknown. Given the broad repertoire of these therapies, there are significant variations in risk analyses, with many guidelines and opinions largely agreeing that cell-depletion therapies likely present the highest risk [65, 66]. At the same time, the discussion of immunology and immunological terms has become more commonplace as mainstream news sources frequently report on developments in vaccines and antigen and antibody tests; this “infodemic” may in turn influence public interest in understanding immunology and immunological health literacy, and interpretations of risk in other contexts [67, 68]. Evidence of the effects of COVID-19 on DMT selection and risk monitoring in MS is a rapidly evolving knowledge base, and communications with PwMS should reflect this.

"The COVID-19 pandemic forced us to rethink our approach in treating MS patients with DMTs. Our initial concerns are readily obvious: Do the current DMTs used in MS patients cause an increased risk of developing COVID-19? Once infected, do the current DMTs in MS cause patients to have worse outcomes than immunocompetent patients? The short answer is that we don't know the answers to these questions yet ... In the absence of robust data, clinicians are forced to have a similar conversation that we had with patients prior to the COVID-19 pandemic: What are the risks/benefits of starting a DMT or for a patient currently taking a DMT?" (John Kramer)

This review had several limitations owing to its limited scope and qualitative nature. The restricted number of survey respondents allowed for a more in-depth, phenomenological approach to the analysis of the free-text
response questions but may have limited applicability to a wider context and was not fit for quantitative analysis. Additionally, performing a targeted literature search enabled the precise unmet need of insufficient patient communications regarding DMT MoAs to be defined; however, the authors acknowledge that these methods are not as robust as a full systematic review.

It is pertinent in this review to recognize and to acknowledge the shifting paradigms in MS theory—in wider understanding both of immunological pathogenesis and of specific immunological MoAs of DMTs—and to ensure that PwMS communications take this into account. For example, MS has historically been considered a demyelinating disease, but recent narratives have shifted towards a whole-brain disease model that considers wider elements of pathogenesis and neurodegeneration [69, 70]. Additionally, it is becoming increasingly clear that even DMTs traditionally thought of as specifically targeting T and/or B cells or other immune components more likely have widespread holistic effects on the immune system [5, 70]. For the sake of transparency and fully informed shared decision-making, it is prudent to acknowledge how the literature has evolved and where gaps remain in our understanding, particularly in individual responses to the therapy and real-world effects.

CONCLUSIONS

Effective communication regarding the MoAs of DMTs has the potential to empower PwMS to take the lead in their therapeutic choices with guidance from HCPs in a shared decision-making model. In addition, our preliminary survey, introduced here, could be implemented in larger cohorts to gather further insights and to quantify findings in order to establish more specific areas of unmet need and to develop best practices for communicating immunology to PwMS.

ACKNOWLEDGEMENTS

Funding. This study (including all digital enhancements and the journal’s Rapid Service Fee) and editorial assistance provided by Jenny Thorp of Oxford PharmaGenesis, Oxford, UK, were supported by Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. Adeline Rosenberg, Marina Ziehn, Brandon Brown, and Jamie L. Weiss developed, conducted, and analyzed the results of the qualitative survey. Jeri Burtchell, Daisy Clemmons, Joann Clemmons, and Tim Sabutis completed the qualitative survey. Jennifer Graves, Michael L. Sweeney, John Kramer, and Ahmed Z. Obeidat provided HCP insights on the results. Adeline Rosenberg conducted the literature review and extracted, contextualized, and analyzed the data. All authors interpreted the results of the qualitative survey and literature review and revised and approved the manuscript. All authors contributed to the article and approved the submitted version.

Prior Presentation. The results of the patient insights survey were first presented at the MS Virtual 8th Joint ACTRIMS-ECTRIMS Meeting 2020 in Burtchell J, Clemmons D, Clemmons J. et al. Patient and health professional perspectives of immune dynamics and MS disease-modifying therapies mode of action throughout COVID-19 pandemic [poster].

Disclosures. Jeri Burtchell has received travel grants from Novartis. Jennifer Graves has received speaker fees from Novartis; Adeline Rosenberg is an employee of Oxford PharmaGenesis, which received funding for medical writing services from Novartis; Michael L. Sweeney has served on speakers’ bureaus for Genentech and Novartis; John Kramer has
received consulting fees and served on speakers’ bureaus for Biogen, Celgene, Genentech, and Novartis; Marina Ziehn and Brandon Brown are employees of Novartis; Jamie L. Weiss was an employee of Novartis at the time of manuscript development and is currently an employee of Prilenia Therapeutics at the time of manuscript revision; Ahmed Z. Obeidat has received consulting fees for advisory boards, steering committees, or speaker fees from Alexion, Biogen, Biologix, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, Novartis, and Sanofi/Genzyme, serves on the editorial board for the International Journal of MS Care, and is the current editor for GENERATIONS (a publication by the Foundation of the Consortium of MS Centers); Daisy Clemmons, Joann Clemmons, and Tim Sabutis have nothing to disclose.

Compliance with Ethics Guidelines. Ethics committee approval was not required for this survey, which was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All survey respondents who are also authors of this publication provided informed consent to participate in the survey and for their responses to be included in this publication. This was a noninterventional qualitative survey conducted by Novartis in the USA to assess PwMS and HCP opinion. The research followed General Data Protection Regulation guidance.

Data Availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636.

2. Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013;10:285–7.

3. Multiple Sclerosis International Federation. Atlas of MS. 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed 09 Feb 2022

4. Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92:e1029–40.

5. Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83:13–26.

6. Burtchell J, Fetty K, Miller K, Minden K, Kantor D. Two sides to every story: perspectives from four patients and a healthcare professional on multiple sclerosis disease progression. Neurol Ther. 2019;8:185–205.

7. Burtchell J, Clemmons D, Clemmons J, et al. Patient and health professional perspectives of immune dynamics and MS disease-modifying therapies mode of action throughout COVID-19 pandemic [poster]. In: Presented at MS virtual 8th joint ACTRIMS-ECTRIMS meeting. 2020.

8. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683–747.

9. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19:696–707.

10. Vasileiadis GK, Dardiotis E, Mavropoulos A, et al. Regulatory B and T lymphocytes in multiple
11. Multiple sclerosis—United Kingdom. Choices—disease modifying therapies. https://www.ms-uk.org/choices-disease-modifying-therapies-content. Accessed 11 Jun 2020

12. MS Society. Making informed decisions about DMTs. 2018. https://www.mssociety.org.uk/research/latest-research/latest-research-news-and-blogs/making-informed-decisions-about-dmts. Accessed 15 Jun 2020

13. Sabatino JJ Jr, Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9:a032037.

14. National Multiple Sclerosis Society. Medications. 2020. https://www.nationalmssociety.org/Treating-MS/Medications. Accessed 11 Jan 2021

15. Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med. 2014;275:350–63.

16. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–40.

17. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011;12(64):213–28.

18. Montalban X, Arnold DL, Weber MS, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med. 2019;380:2406–17.

19. Bayas A, Maurer M. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence. Patient Prefer Adherence. 2015;9:265–74.

20. Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler. 2017;23:185–90.

21. Heesen C, Solari A, Giordano A, Kasper J, Kopke S. Decisions on treatment complexities in multiple sclerosis immunotherapy: new treatment options urge patient engagement. J Neurol Sci. 2011;16:1507–12.

22. Reen GK, Silber E, Langdon DW. Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107–22.

23. Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020;39:101929.

24. de Ceuninck van Capelle A, Meide HV, Vosman FJH, Visser LH. A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT’s) in multiple sclerosis (MS). PLoS ONE. 2017;12:e0182806.

25. Falet J, Deshmukh SR, Babinski M, et al. A qualitative study of patient perspectives regarding the role of the neurologist in advanced multiple sclerosis. In: S3rd Annual congress of the Canadian Neurological Sciences Federation: Can J Neurol; 2018. p. S24

26. Johnson K, Kuehn CM, Yorkston KM, et al. Patient perspectives on disease-modifying therapy in multiple sclerosis. Int J MS Care. 2006;8:11–18.

27. Schlegel V, Leray E. From medical prescription to patient compliance: a qualitative insight into the neurologist-patient relationship in multiple sclerosis. Int J MS Care. 2018;20:279–86.

28. Tencer T, Will O, Nguyen J et al. Neurologist and patient preferences in multiple sclerosis: UK and US qualitative research findings. In: ISPOR Europe 2019: Value Health; 2019, p. S757

29. Members of the MS in the 21st Century Steering Group., Rieckmann P, Centonze D, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2018;19:153–60.

30. Adlard NE, Panpurina A, Patel VJ, Khurana V. Patient preferences for different modes and frequency of administration of multiple sclerosis disease modifying therapies. In: ISPOR Europe 2018: new perspective for improving 21st century health systems: Value Health; 2018;S351(PND351).

31. Bergmann A, Lang M, Ludger Bischoff C, et al. Patient preferences in the choice of disease modifying drugs for multiple sclerosis. In: 66th American Academy of Neurology annual meeting, AAN: Neurology; 2014, p. P3.137.

32. Carlin C, Higuera L, Anderson S. Improving patient-centred care by assessing patient preference for multiple sclerosis disease-modifying agents: a stated-choice experiment. Perm J. 2017;21:16–102.

33. Garcia-Dominguez JM, Munoz D, Comellas M, et al. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adherence. 2016;10:1945–56.

34. Hincapie AL, Penn J, Burns CF. Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis. J Manag Care Spec Pharm. 2017;23:822–30.
35. Jonker MF, Donkers B, Goossens LMA, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Mak. 2020;40:198–211.

36. Bottomley C, Lloyd A, Bennett G, Adlard N. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in multiple sclerosis. J Med Econ. 2017;20:863–70.

37. Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7:263–75.

38. Wilson L, Loucks A, Bui C, et al. Patient centred decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014;344:80–7.

39. Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17:74–82.

40. Clark LA, Gabriele S, Brown H, et al. Understanding disease-modifying therapy administration route suitability in different multiple sclerosis patient segments in the EU and US. In: ISPOR 2019: Value Health; 2017, p. S378

41. Serafini P, Jones E, Pike J. Assessment of patient preferences in the treatment of relapsing-remitting multiple sclerosis in public and private systems in Latin America. In: ISPOR 19th annual European congress: Value Health; 2016, p. A435

42. de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence. 2012;6:263–73.

43. Glusman MB, Roberg B, Thelen J, et al. Patient-provider communication and perceived autonomy support among multiple sclerosis patients who discontinue disease modifying therapy against medical advice. In: 31st Congress of the European Committee for treatment and research in multiple sclerosis, ECTRIMS: Mult Scler; 2015, p. 278

44. Nazareth TA, Rava AR, Polyaakov JL, et al. Relapse prevalence, symptoms, and health care engagement: patient insights from the multiple sclerosis in America 2017 survey. Mult Scler Relat Disord. 2018;26:219–34.

45. Rinon A, Buch M, Holley D, Verdun E. The MS choices survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629–43.

46. Sempere AP, Vera-Lopez V, Gimenez-Martinez J, et al. Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study. Patient Prefer Adherence. 2017;11:995–9.

47. Tintore M, Alexander M, Costello K, et al. The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence. 2017;11:33–45.

48. Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138.

49. Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17:696–707.

50. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler. 2010;16:1507–12.

51. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256:554–62.

52. Kasper J, Kopke S, Muhlhauser I, Nubling M, Heesen C. Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. Eur J Neurol. 2008;15:1345–52.

53. Kopke S, Kern S, Ziemssen T, et al. Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2014;85:411–8.

54. Poulos C, Kinter E, Yang JC, et al. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. Patient. 2016;9:171–80.

55. Poulos C, Kinter E, Yang JC, et al. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Ther Adv Neurol Disord. 2016;9:95–104.

56. Thakur K, Manuel L, Tomlinson M. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro 30G and Betacomfort(®) devices. Pragmat Obs Res. 2013;4:19–26.

57. Wicks P, Thomas NP, Kotowksy N, et al. US patient perspectives on the multiple sclerosis treatment
experience: results of a US web-based survey. In: 31st Congress of the European committee for treatment and research in multiple sclerosis, ECTRIMS: Mult Scler; 2015, p. 278.

58. Wicks P, Brandes D, Park J, et al. Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients. Interact J Med Res. 2015;4:e6.

59. Stacey D, Hill S, McCaffery K, et al. Shared decision making interventions: theoretical and empirical evidence with implications for health literacy. Stud Health Technol Inform. 2017;240:263–83.

60. Kopke S, Solari A, Rahn A, et al. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev. 2018;10:CD008757.

61. National Institute for Health and Care Excellence. Shared decision making. 2021. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/shared-decision-making. Accessed 15 Jan 2021.

62. NHS England. Shared decision making to improve health outcomes. https://www.england.nhs.uk/shared-decision-making/why-is-shared-decision-making-important/shared-decision-making-to-improve-health-outcomes/. Accessed 2 Nov 2020.

63. Armstrong MJ, Shulman LM, Vandigo J, Mullins CD. Patient engagement and shared decision-making: what do they look like in neurology practice? Neurol Clin Pract. 2016;6:190–7.

64. Bomhof-Roordink H, Gartner FR, Stiggelbout AM, Pieterse AH. Key components of shared decision making models: a systematic review. BMJ Open. 2019;9:e031763.

65. Giovannoni G, Hawkes C, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073.

66. Zrzavy T, Wimmer I, Rommer PS, Berger T. Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. Eur J Neurol. 2021;28:3503–16.

67. Osier F, Ting JPY, Fraser J, et al. The global response to the COVID-19 pandemic: how have immunology societies contributed? Nat Rev Immunol. 2020;20:594–602.

68. Okan O, Bollweg TM, Berens EM, et al. Coronavirus-related health literacy: a cross-sectional study in adults during the COVID-19 infodemic in Germany. Int J Environ Res Public Health. 2020;17:5503.

69. Barnett MH, Sutton I. The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol. 2006;19:242–7.

70. Comi G, Bar-Or A, Lassmann H, et al. The role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89:13–23.